SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization declines year over year

Q3 FY2026 depreciation & amortization of $152K fell 97.9% year over year, in line with the -97.9% change in trailing-twelve-month depreciation & amortization.

Context

  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -97.9% holds above the trailing-twelve-month pace of -97.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$152K— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMSep 2026
$152K-97.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-97.9%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
-100.0%

Depreciation & Amortization vs competitors

How SLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.9% is the 9th highest of 10, against a peer median of +8.6%.
SLS Competitors
Depreciation & Amortization for SLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$98.28M USD+8.6%+11.2%1.7%
AAPGAscentage Pharma Group InternationalFY2025CN¥86.48M CNY-7.2%+11.2%15.5%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$15.87M USD-14.3%+20.4%2.3%
MGNXMacroGenics, Inc.LTM Mar 2026$6.94M USD-7.1%-22.5%4.4%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$4.6M USD+18.5%+29.8%2.0%
IMNMImmunome, Inc.LTM Sep 2026$3.76M USD+35.4%+67.3%—
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$3.59M USD———
CCCCC4 Therapeutics, Inc.LTM Mar 2026$3.38M USD+84.9%+5.3%9.7%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$1.53M USD+180.4%+0.4%9.2%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$152K USD-97.9%——
CBIOCrescent Biopharma, Inc.LTM Mar 2026$148K USD-99.6%-26.0%1.2%
Peer median (excluding SLS) —+8.6%+11.2%3.3%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Depreciation & Amortization1.27M457K37.87M31.51M0
Deferred Income Tax(239K)(457K)000
Stock-Based Compensation1.01M1.73M1.39M1.56M1.96M
Change in Working Capital(7.62M)5.64M3.35M(6.65M)(4.08M)
Accounts Receivables00000
Inventory00000
Accounts Payables(2.51M)1.21M2.3M(2.14M)(535K)
Other Working Capital(5.1M)4.43M1.04M(4.51M)(3.54M)
Other Non-Cash Items248K10.13M(36.67M)(30.95M)597K
Operating Cash Flow(26.02M)(23.81M)(31.41M)(35.4M)(28.39M)
Capital Expenditures0(4.5M)(5.5M)00
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(4.5M)(5.5M)00
Debt Repayment00000
Common Stock Issued9.01M23.99M22.23M46.16M86.82M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.07M85K90K594K(527K)
Financing Cash Flow12.07M24.08M22.32M46.76M86.3M
Effect of Forex Changes00000
Net Change in Cash(13.95M)(4.23M)(14.6M)11.36M57.91M
Free Cash Flow(26.02M)(28.31M)(36.91M)(35.4M)(28.39M)

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.